ENGERIX-B 20 mikrogramov/1 ml suspenzija za injiciranje Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

engerix-b 20 mikrogramov/1 ml suspenzija za injiciranje

gsk d.o.o., ljubljana - antigen virusa hepatitisa b, rekombinantni, površinski - suspenzija za injiciranje - antigen virusa hepatitisa b, rekombinantni, površinski 20 µg / 1 ml - prečiščen antigen virusa hepatitisa tipa b

ENGERIX-B za otroke 10 mikrogramov/0,5 ml suspenzija za injiciranje Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

engerix-b za otroke 10 mikrogramov/0,5 ml suspenzija za injiciranje

gsk d.o.o., ljubljana - antigen virusa hepatitisa b, rekombinantni, površinski - suspenzija za injiciranje - antigen virusa hepatitisa b, rekombinantni, površinski 10 µg / 0,5 ml - prečiščen antigen virusa hepatitisa tipa b

ENGERIX-B 20 mikrogramov/1 ml suspenzija za injiciranje Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

engerix-b 20 mikrogramov/1 ml suspenzija za injiciranje

gsk d.o.o., ljubljana - antigen virusa hepatitisa b, rekombinantni, površinski - suspenzija za injiciranje - antigen virusa hepatitisa b, rekombinantni, površinski 20 µg / 1 ml - prečiščen antigen virusa hepatitisa tipa b

Fendrix Evropska unija - slovenščina - EMA (European Medicines Agency)

fendrix

glaxosmithkline biologicals s.a. - površinski antigen hepatitisa b - hepatitis b; immunization - cepiva - fendrix je indicirano pri mladostnikih in odraslih v starosti od 15 let naprej, za aktivne imunizacije proti okužbe z virusom hepatitisa b (hbv) posledica vse znane podtipov za bolnike z ledvičnim (vključno s pre-hemodializni in hemodializnega bolniki).

HBVaxPro Evropska unija - slovenščina - EMA (European Medicines Agency)

hbvaxpro

merck sharp & dohme b.v.  - hepatitis b, rekombinantni površinski antigen - hepatitis b; immunization - cepiva - 5 micrograms hbvaxpro is indicated for active immunisation against hepatitis-b-virus infection caused by all known subtypes in individuals from birth through 15 years of age considered at risk of exposure to hepatitis-b virus. posebno ogroženih kategorij, da se immunised določi na podlagi uradnih priporočil. pričakovati je, da se hepatitis d bo prav tako mogoče preprečiti z imunizacijo z hbvaxpro, kot je hepatitis d (zaradi delta agent) ne pride v odsotnosti hepatitis-b, okužbe. 10 micrograms hbvaxpro is indicated for active immunisation against hepatitis-b-virus infection caused by all known subtypes in individuals 16 years of age or more considered at risk of exposure to hepatitis-b virus. posebno ogroženih kategorij, da se immunised določi na podlagi uradnih priporočil. pričakovati je, da se hepatitis d bo prav tako mogoče preprečiti z imunizacijo z hbvaxpro, kot je hepatitis d (zaradi delta agent) ne pride v odsotnosti hepatitis-b, okužbe. 40 micrograms hbvaxpro is indicated for the active immunisation against hepatitis-b-virus infection caused by all known subtypes in predialysis and dialysis adult patients. pričakovati je, da se hepatitis d bo prav tako mogoče preprečiti z imunizacijo z hbvaxpro, kot je hepatitis d (zaradi delta agent) ne pride v odsotnosti hepatitis b okužbe.

Heplisav B Evropska unija - slovenščina - EMA (European Medicines Agency)

heplisav b

dynavax gmbh - površinski antigen hepatitisa b - hepatitis b - cepiva - heplisav b is indicated for the active immunisation against hepatitis b virus infection (hbv) caused by all known subtypes of hepatitis b virus in adults 18 years of age and older. the use of heplisav b should be in accordance with official recommendations. it can be expected that hepatitis d will also be prevented by immunisation with heplisav b as hepatitis d (caused by the delta agent) does not occur in the absence of hepatitis b infection.

PreHevbri Evropska unija - slovenščina - EMA (European Medicines Agency)

prehevbri

vbi vaccines b.v. - površinski antigen hepatitisa b - hepatitis b - cepiva - prehevbri is indicated for active immunisation against infection caused by all known subtypes of the hepatitis b virus in adults. it can be expected that hepatitis d will also be prevented by immunisation with prehevbri as hepatitis d (caused by the delta agent) does not occur in the absence of hepatitis b infection. the use of prehevbri should be in accordance with official recommendations.